Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer (RTL-DART)

University Health Network, Toronto

Status: Enrolling

Conditions: Squamous Cell Cancer of Head and Neck (SCCHN)

Treatments: Radiation: Image guided radiation therapy; Radiation: Daily adaptive radiation therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07348887

25-5273

Details and patient eligibility

About

This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer

Full description

This study will recruit up to 50 patients planned to receive curative (chemo) radiotherapy for (head and neck squamous cell carcinoma) HNSCC with at least one level 1b lesion not being treated electively and with no high dose structure <1cm to spared (submandibular gland) SMG. The effect of daily ART with SMG dose sparing will be studied using both doimetric analysis and externally-validated quantitative metrics of unstimulated salivary flow as an object assessment for submandibular gland function. Patient report outcomes will assess the effect of the intervention on self-reported quality of life following treatment.

Patients, at the time of enrollment, will be randomized into one of the two treatment arms. The patients will be blinded to prevent bias in their quality of life assessments.

Patients in both arms will undergo a baseline functional CT scan along with other assessments including oral and dental assessment, PSS-HNC swallow assessment, unstimulated salivary flow rate test, DMFS160 index, and quality of life questionnaire. The radiation treatment will take approximately 7 weeks to complete. The follow up visits will be at 1.5, 6, 12, and 24 months with assessments similar to baseline.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• Histologically proven Squamous Cell carcinoma of head and neck
• Bilateral neck being treated
• At least one level 1b not being treated electively and with no target structure, other than elective level II/III, <1cm to spared SMG
• ECOG PS 0-2
• Planned for curative (chemo)radiotherapy
• Able to receive and understand verbal and written information regarding study and able to give written informed consent
• Be able to lie comfortably on back and to wear immobilization for up to 1 hour

Exclusion criteria

• As judged by investigator evidence of systemic disease that makes unsuitable for study
• Pregnancy
• Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

50 participants in 2 patient groups

Image guided radiation therapy

Active Comparator group

Description:

This arm will proceed as per the standard of care. The pre-treatment reference plan will be delivered daily for 35 fractions. If a notable change in anatomy is identified, a dose of the day calculation may be performed as per current standard head and neck workflow

Treatment:

Radiation: Image guided radiation therapy

Daily Adaptive Radiation Therapy

Experimental group

Description:

Structures of daily adaptive radiation therapy organ at risk will be AI generated in the Ethos platform on the daily CBCT and then edited by radiation therapy team as required. A rigid registration of CTV targets to the CBCT replicating the current radiation therapy led IGRT process.

Treatment:

Radiation: Daily adaptive radiation therapy